首页 | 本学科首页   官方微博 | 高级检索  
     

超声造影结合定量分析法及血清TSH、Gal-3、CK-19诊断甲状腺微小乳头状癌的临床价值
引用本文:韩云霞,李雪梅,欧阳向柳,张春英,郑立春. 超声造影结合定量分析法及血清TSH、Gal-3、CK-19诊断甲状腺微小乳头状癌的临床价值[J]. 中国现代医学杂志, 2023, 0(16): 84-91
作者姓名:韩云霞  李雪梅  欧阳向柳  张春英  郑立春
作者单位:1.唐山市工人医院,超声医学科,河北 唐山 063000;2.唐山市工人医院,病理科,河北 唐山 063000;3.唐山市工人医院,头颈外科,河北 唐山 063000;4.唐山市工人医院,核医学科,河北 唐山 063000
基金项目:河北省自然科学基金(No:H2020209193);河北省医学科学研究课题(No:20201517)
摘    要:目的 探讨超声造影(CEUS)结合定量分析法及血清促甲状腺激素(TSH)、半乳糖凝集素3(Gal-3)、细胞角蛋白(CK-19)诊断甲状腺微小乳头状癌(PTMC)的临床价值。方法 回顾性分析2019年4月—2022年4月于唐山市工人医院行手术治疗的128例甲状腺微小结节患者的临床资料,其中59例PTMC患者作为PTMC组,69例甲状腺肿伴乳头状增生患者作为良性组。两组患者入院后均接受CEUS检查,以化学发光免疫法检测血清TSH,以免疫组织化学SP法检测Gal-3、CK-19表达。比较两组CEUS特征(增强顺序、消退模式、增强模式、环形增强、达峰强度、均匀增强)及参数[灌注峰值(Peak)、达峰时间(TP)、灌注率(Shapness)、曲线下面积(AUC)],比较两组血清TSH水平与Gal-3、CK19表达情况,通过受试者工作特征(ROC)曲线分析CEUS参数及血清TSH水平诊断PTMC的价值。最后以临床诊断结果为金标准,通过一致性分析Gal-3、CK-19单独及CEUS参数、TSH、Gal-3、CK-19联合诊断PTMC的效能。结果 PTMC组增强顺序向心性、消退模式快出、增强模式慢进...

关 键 词:甲状腺微小乳头状癌  甲状腺微小结节  超声造影  促甲状腺激素  半乳糖凝集素3  细胞角蛋白  诊断
收稿时间:2023-01-17

Value of quantitative analysis by CEUS and serum TSH, Gal-3, and CK-19 in the diagnosis of papillary thyroid microcarcinoma
Han Yun-xi,Li Xue-mei,Ouyang Xiang-liu,Zhang Chun-ying,Zheng Li-chun. Value of quantitative analysis by CEUS and serum TSH, Gal-3, and CK-19 in the diagnosis of papillary thyroid microcarcinoma[J]. China Journal of Modern Medicine, 2023, 0(16): 84-91
Authors:Han Yun-xi  Li Xue-mei  Ouyang Xiang-liu  Zhang Chun-ying  Zheng Li-chun
Affiliation:1.Department of Ultrasonic Medicine, Tangshan Workers'' Hospital, Tangshan, Hebei 063000, China;2.Department of Pathology, Tangshan Workers'' Hospital, Tangshan, Hebei 063000, China;3.Department of Head and Neck Surgery, Tangshan Workers'' Hospital, Tangshan, Hebei 063000, China;4.Department of Nuclear Medicine, Tangshan Workers'' Hospital, Tangshan, Hebei 063000, China
Abstract:Objective To investigate the value of quantitative analysis by contrast-enhanced ultrasound (CEUS) and serum thyroid stimulating hormone (TSH), galectin-3 (Gal-3), and cytokeratin-19 (CK-19) in the diagnosis of papillary thyroid microcarcinoma (PTMC).Methods Clinical data of 128 patients with thyroid micronodules who underwent surgical treatment in our hospital from April 2019 to April 2022 were retrospectively analyzed, among which 59 patients with PTMC were included in the PTMC group (n = 59), and 69 patients with goiter accompanied by papillary thyroid hyperplasia were included in the benign group (n = 69). Both groups of patients received CEUS after admission. The serum level of TSH was detected by chemiluminescence immunoassay, and the levels of Gal-3 and CK-19 were detected by immunohistochemistry with the streptavidin-peroxidase (SP) method. The CEUS characteristics (sequence of enhancement, washout pattern, enhancement pattern, ring enhancement, peak intensity, and uniform enhancement) and parameters [peak, time to peak (TP), sharpness, and area under the curve (AUC)] were compared between the two groups. Serum levels of TSH, Gal-3 and CK-19 were also compared between the two groups. The value of CEUS parameters and the serum level of TSH in the diagnosis of PTMC was analyzed by receiver operating characteristic (ROC) curve. The clinical diagnosis was set as the gold standard, and the efficacy of Gal-3 or CK-19 alone and that of the combination of CEUS parameters, TSH, Gal-3, and CK-19 in the diagnosis of PTMC were analyzed by agreement analysis.Results The proportions of centripetal enhancement, fast washout, slow enhancement, absence of ring enhancement, low enhancement at peak and absence of uniform enhancement in the PTMC group were higher than those in the benign group (P < 0.05). The peak and AUC in the PTMC group were lower than those in the benign group (P < 0.05). There was no difference in TP and sharpness between the PTMC group and the benign group (P > 0.05). The serum level of TSH in the PTMC group was higher than that in the benign group (P < 0.05). The positive rates of Gal-3 and CK-19 in the PTMC group were higher than those in the benign group (P < 0.05). As shown in the ROC curve analysis, the sensitivities of peak, AUC and the level of TSH for diagnosing PTMC were 55.1% (95% CI: 0.489, 0.697), 63.8% (95% CI: 0.608, 0.761), and 62.3% (95% CI: 0.724, 0.848), with the specificities being 77.2% (95% CI: 0.492, 0.701), 74.6% (95% CI: 0.610, 0.788), 96.6% (95% CI: 0.729, 0.859), and the areas under the ROC curves being 0.615 (95% CI: 0.517, 0.713), 0.708 (95% CI: 0.618, 0.798), 0.810 (95% CI: 0.733, 0.887), respectively. The sensitivity, specificity and accuracy of Gal-3 in diagnosing PTMC were 93.2% (55/59), 94.2% (65/69), and 93.8% (120/128) (K = 0.874), respectively. The sensitivity, specificity and accuracy of CK19 for the diagnosis of PTMC were 91.5% (54/59), 89.9% (62/69), and 90.6% (116/128) (K = 0.812), respectively. The sensitivity, specificity and accuracy of CEUS parameters combined with TSH, Gal-3 and CK19 in the diagnosis of PTMC were 96.6 (59/59), 97.1 (67/69), and 96.9 (124/128) (K = 0.937), respectively.Conclusions CEUS parameters and levels of TSH, Gal-3, and CK-19 can all be applied in the diagnosis of PTMC. However, the agreement analysis suggests that the diagnostic efficacy of the combination of all indicators is superior to that of any single indicator with higher sensitivity and specificity, which should be paid attention to among clinicians.
Keywords:papillary thyroid microcarcinoma  thyroid micronodules  contrast-enhanced ultrasound  thyroid stimulating hormone  galectin-3  cytokeratin  diagnosis
点击此处可从《中国现代医学杂志》浏览原始摘要信息
点击此处可从《中国现代医学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号